Carroll University
[photo] Main Hall
Program Home
About the Program
Online Catalog
Faculty Profile


Schneider, Christine L., PhD

Assistant Professor
Office: Rankin B01
Office Phone: 262-524-7278
B.S. - Biochemistry, University of Wisconsin Madison 1989
B.S. - Molecular Biology, University of Wisconsin Madison 1989

M.S. - Biology and Microbiology, University of Wisconsin Oshkosh 2002
Ph. D. - Microbiology and Molecular Genetics, Medical College of Wisconsin 2011
Areas of Specialization:
Immune evasion strategies of human herpesviruses, microbiology, virology, immunology, genetics, and cell biology.
Scholarly and Professional Achievements:
Sturgill ER, Malouli D, Hansen SG, Burwitz BJ, Schneider CL, Womack JL, Verweij MC, Ventura AB, Jeffries K, Legasse AW, Axthelm MK, Hudson AW, Sacha JB, Picker LJ, Fruh K. Natural Killer Cell Evasion is Essential for Primary Infection by Rhesus Cytomegalovirus. Submitted for publication to PLOS pathogens June 2015.

Schneider CL. To Screen or not to Screen: The Application of Genomics to Breast Cancer Diagnosis and Treatment. Submitted to the National Center for Case Study Teaching in Science, University at Buffalo Biological Sciences in June 2015.

Heiss, BE* and CL Schneider. Generation of expression constructs to identify ER retention motifs in the Human Herpesvirus 7 U20 protein. BIOS 2015 accepted for publication in September issue * indicates undergraduate student

Mellergaard M, Skovbakke SL, Schneider CL, Lauridsen F, Andresen L, Jensen H, Skov S. N-glycosylation of asparagine N8 regulates surface expression of MHC class I chain-related protein A (MICA) alleles dependent on threonine T24. J Biol Chem. 2014 May 28. pii: jbc.M114.573238.

Schneider, CL, Hudson, AW. The Human Herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated Cytotoxicity through modulation of MICA and MICB. PLoS pathog. 2011 Nov; 7(11):e1002362

Glosson NL, Gonyo P, May NA, Schneider CL, Ristow LC, Wang Q, Hudson AW. Insight into the mechanism of HHV-7 U21-mediated diversion of class I MHC molecules to lysosomes. J Biol Chem. 2010 Nov 19;285(47):37016-29.

LaCount DJ, Hanson SF, Schneider CL, Friesen PD. Caspase inhibitor P35 and inhibitor of apoptosis Op-IAP block in vivo proteolytic activation of an effector caspase at different steps. J Biol Chem. 2000 May 26;275(21):15657-64.

Fisher AJ, Cruz W, Zoog SJ, Schneider CL, Friesen PD. Crystal structure of baculovirus P35: role of a novel reactive site loop in apoptotic caspase inhibition. EMBO J. 1999 Apr 15;18(8):2031-9.

Staszewski S, Massari FE, Kober A, Gohler R, Durr S, Anderson KW, Schneider CL, Waterbury JA, Bakshi KK, Taylor VI, et al. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis. 1995 May;171(5):1159-65.

Byrnes VW, Emini EA, Schleif WA, Condra JH, Schneider CL, Long WJ, Wolfgang JA, Graham DJ, Gotlib L, Schlabach AJ, et al. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob Agents Chemother. 1994 Jun;38(6):1404-7.

Schleif WA, Murthy KK, Sardana VV, Schneider CL, Byrnes VW, Cobb KE, Roth E, Wolfgang JA, Hoffman JM, Smith AM, et al. Attempted prophylaxis of human immunodeficiency virus type 1 infection in chimpanzees with a nonnucleoside reverse transcriptase inhibitor. AIDS Res Hum Retroviruses. 1994 Jan;10(1):107-10.

Byrnes VW, Sardana VV, Schleif WA, Condra JH, Waterbury JA, Wolfgang JA, Long WJ, Schneider CL, Schlabach AJ, Wolanski BS, et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother. 1993 Aug;37(8):1576-9.

LaFemina RL, Schneider CL, Robbins HL, Callahan PL, LeGrow K, Roth E, Schleif WA, Emini EA. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol. 1992 Dec;66(12):7414-9.

Manam S, Shinder GA, Joslyn DJ, Kraynak AR, Hammermeister CL, Leander KR, Ledwith BJ, Prahalada S, van Zwieten MJ, Nichols WW. Dose-related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors. Carcinogenesis. 1995 May;16(5):1113-9.

Takagi H, Sharp R, Hammermeister C, Goodrow T, Bradley MO, Fausto N, Merlino G. Molecular and genetic analysis of liver oncogenesis in transforming growth factor alpha transgenic mice. Cancer Res. 1992 Oct 1;52(19):5171-7.

Manam S, Storer RD, Prahalada S, Leander KR, Kraynak AR, Hammermeister CL, Joslyn DJ, Ledwith BJ, van Zwieten MJ, Bradley MO, et al. Activation of the Ki-ras gene in spontaneous and chemically induced lung tumors in CD-1 mice. Mol Carcinog. 1992;6(1):68-75.

Posters and Presentations:

Schneider, CL, Heiss, BE*, and Hudson, AW. The ER-lumenal domain of Human Herpesvirus 7 U20 is sufficient for ER retention. ASM 2015, New Orleans, LS. * indicates undergraduate student.

Schneider, CL, Hudson, AW. Presentation: HHV-7 U21 is a multifunctional immunoevasin that disrupts the trafficking of NK activating ligands in addition to class I MHC. Betaherpesviruses satellite session at the 36th annual International Herpesvirus Workshop 2010 conference, Salt Lake City, UT.

Schneider, CL, Hudson, AW. Presentation: The HHV-7 Immunoevasin U21 Directs ULBP1 to Lysosomes. 3rd Annual Center for Human Immunology Symposium, Milwaukee, WI. "Outstanding Abstract" awardee.

Schneider, CL, Hudson, AW. Poster: Characterization of the HHV-6B U20 open reading frame. 12th annual International Cytomegalovirus/Betaherpesvirus workshop 2009, Boston, MA.

Schneider, CL, Hudson, AW. Presentation: Characterization of the HHV-6 and HHV-7 U20 open reading frames. International conference on HHV-6 & 7, Baltimore, MD.
I joined the Biology program at Carroll University in 2011. I began my career in industry working at Merck in Lansdale PA first in the safety assessment group and then in the antiviral group working on HIV clinical trials of a novel reverse transcription inhibitor. I left Merck after the birth of my son and moved back to Sun Prairie Wisconsin to be near family. I worked as a technician in a lab at UW Madison that studied apoptosis then relocated to the Appleton area for my husband's work. While in Appleton I went back for my MS in Biology at UW Oshkosh and worked in the Skin Science group at Kimberly Clark.  We then relocated to the Milwaukee area and I returned to school at the Medical College of Wisconsin to get my PhD so that I could realize my dream of teaching at an institution like Carroll.

At Carroll I have continued research in my area of expertise by maintaining an active collaboration with my thesis mentor Dr. Amy Hudson at MCW. While this collaboration is valuable and has led to various publications, it was also important to me to develop an independent research track that would be self-sustainable. As a virologist I turned my attention to viruses that infect bacteria (phage). Phage are interesting for a variety of reasons and I designed research projects that have clinical relevance in today's world. One project examines the global problem of antibiotic resistance and the role that phage may play in transmitting antibiotic resistance genes between bacterial species in environmental waterways. The other project focuses on identifying and characterizing phage that can infect and kill Pseudomonas aeruginosa. P. aeruginosa is a bacteria that causes many hospital acquired infections, and multidrug resistant strains are on the rise. The bacterium is also a common pathogen in cystic fibrosis patients. By characterizing new phage that kill P. aeruginosa, we may identify phage that could be used in the future to treat infections by phage therapy as an alternative to antibiotics. My research has created opportunities for students- I have mentored four students either through BIO485 or the Pioneer Scholar and StaR Scholar programs. These students have presented their data at Celebrate Carroll, regional and national meetings and submitted manuscripts for publication.

As an instructor, I embrace technology as a tool to improve student learning. I served as a technology fellow for the Life Sciences department and continue to seek out ways to use technology in a way that benefits the student. I was involved in the initial testing of Mediasite, our new lecture capture system at Carroll, and will be implementing in my Genetics course to give students the ability to watch the lectures outside of the normal class period at their own pace. As a member of the Faculty Development Committee I hope to use the expertise I gain to help other faculty who are interested in adopting new technology in their classes.
Service to Carroll University or the Profession:
FDC- (2014 - present)
Technology fellowship (2013)
VA Institutional Biosafety Committee- community member since 2014
Honors and Awards:
Faculty Development grants (2 grants; 2015)
Pioneer Scholar Grants for Student Faculty Research (2 grants; 2015)
STAR scholar grant for student-faculty research (2013)
Technology fellowship (2013)
Title III pathways to success stipend. "Redesigning courses to deepen student learning" workshop (2013)

Last updated 7/20/2015

 Copyright © 2015 Carroll University, Waukesha, Wisconsin. All rights reserved. Top of Page